This is the current revision of this page, as edited by Entranced98 (talk | contribs) at 00:09, 15 June 2023 (Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"). The present address (URL) is a permanent link to this version.
Revision as of 00:09, 15 June 2023 by Entranced98 (talk | contribs) (Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound")(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Monoclonal antibody Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD80 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| (what is this?) (verify) | |
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
References
- Ebadi M, Sadeghi MA, Reddy NM, Rezaei N (2020). "Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma". In Rezaei M (ed.). Cancer immunology: cancer immunotherapy for organ-specific tumors (Second ed.). Cham: Springer Nature. p. 178. ISBN 978-3-03-057949-4.
- "Biogen Idec: Pipeline". Archived from the original on 2008-05-17. Retrieved 2009-09-24.
- WHO Drug Information
External links
| Immunosuppressive drugs / Immunosuppressants (L04) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |